UBS AM’s Juno Therapeutics, Inc. JUNO Stock Holding History

UBS AM’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-58,690	Closed	-$2.68M	–	2694
2017 Q4	$2.68M	Buy	58,690 +963	+2%	+$48K	﹤0.01%	1313
2017 Q3	$2.59M	Buy	57,727 +4,288	+8%	+$146K	﹤0.01%	1300
2017 Q2	$1.6M	Buy	53,439 +23,539	+79%	+$581K	﹤0.01%	1445
2017 Q1	$663K	Buy	29,900 +12,947	+76%	+$278K	﹤0.01%	1774
2016 Q4	$320K	Sell	16,953 -18,511	-52%	-$453K	﹤0.01%	1926
2016 Q3	$1.06M	Hold	35,464	–	–	﹤0.01%	1669
2016 Q2	$1.36M	Buy	35,464 +16,064	+83%	+$667K	﹤0.01%	1510
2016 Q1	$739K	Sell	19,400 -116,022	-86%	-$4.04M	﹤0.01%	1762
2015 Q4	$5.96M	Buy	135,422 +25,824	+24%	+$1.28M	0.01%	1014
2015 Q3	$4.46M	Buy	109,598 +45,117	+70%	+$1.98M	﹤0.01%	1102
2015 Q2	$3.44M	Sell	64,481 -969	-1%	-$51.4K	﹤0.01%	1181
2015 Q1	$3.97M	Sell	65,450 -31,950	-33%	-$1.55M	﹤0.01%	1105
2014 Q4	$5.09M	Buy	+97,400	New	+$4.36M	﹤0.01%	1034

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

UBS AM's JUNO Position: Q1 2018 in Review

UBS AM sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 58,690 shares — an estimated $2.68M sold.

UBS AM first reported a position in JUNO in Q4 2014 and held it in 13 quarters. The position peaked at $5.96M in Q4 2015. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

UBS AM reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
UBS AM sold 58,690 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $2.68M.
UBS AM first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 13 quarters.
UBS AM's Juno Therapeutics, Inc. position peaked at $5.96M in Q4 2015.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on UBS AM's 13F filing for Q1 2018, filed 14 May 2018.